- Home
- AIFF vs HOOK Comparison
AIFF vs HOOK Comparison
Compare AIFF & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- HOOK
- Stock Information
- Founded
- AIFF 2006
- HOOK 2011
- Country
- AIFF Canada
- HOOK United States
- Employees
- AIFF N/A
- HOOK N/A
- Industry
- AIFF
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- HOOK Health Care
- Exchange
- AIFF NYSE
- HOOK Nasdaq
- Market Cap
- AIFF 26.6M
- HOOK 24.5M
- IPO Year
- AIFF N/A
- HOOK 2019
- Fundamental
- Price
- AIFF $7.79
- HOOK $1.78
- Analyst Decision
- AIFF
- HOOK Buy
- Analyst Count
- AIFF 0
- HOOK 4
- Target Price
- AIFF N/A
- HOOK $10.67
- AVG Volume (30 Days)
- AIFF 18.1M
- HOOK 44.7K
- Earning Date
- AIFF 03-04-2025
- HOOK 03-21-2025
- Dividend Yield
- AIFF N/A
- HOOK N/A
- EPS Growth
- AIFF N/A
- HOOK N/A
- EPS
- AIFF N/A
- HOOK N/A
- Revenue
- AIFF $74,000.00
- HOOK $49,999,000.00
- Revenue This Year
- AIFF N/A
- HOOK $148.80
- Revenue Next Year
- AIFF N/A
- HOOK N/A
- P/E Ratio
- AIFF N/A
- HOOK N/A
- Revenue Growth
- AIFF N/A
- HOOK 143.30
- 52 Week Low
- AIFF $1.86
- HOOK $1.65
- 52 Week High
- AIFF $17.20
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- AIFF 55.76
- HOOK 41.23
- Support Level
- AIFF $7.11
- HOOK $1.77
- Resistance Level
- AIFF $17.20
- HOOK $1.96
- Average True Range (ATR)
- AIFF 2.04
- HOOK 0.12
- MACD
- AIFF 0.15
- HOOK 0.00
- Stochastic Oscillator
- AIFF 33.45
- HOOK 41.40
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.